CRANBURY, N.J.– Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the appointment of Martin L. Wilson as General Counsel, Chief Compliance Officer and Senior Vice President. Mr. Wilson brings nearly 20 years of legal, compliance and executive experience and accomplishment within the life sciences industry. Mr. Wilson will be responsible for the Legal and Compliance functions and serve as a key member of the leadership team.
“The Rocket family is thrilled to welcome Martin to our talented executive leadership team as we advance our world-class pipeline of gene therapies and unlock cures for patients facing devastating rare disease,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma. “Martin’s vast legal and compliance expertise, coupled with exceptional leadership experiences at life science companies of varying sizes, scales our existing capabilities as we rapidly expand in support of our ambition to seek gene therapy cures.”
Prior to joining Rocket, Mr. Wilson was General Counsel and Chief Corporate Officer at Ichnos Sciences, where he oversaw Legal, Compliance, Business Development, Human Resources and IT. Mr. Wilson helped establish Ichnos as an independent corporate entity and set up its corporate structure. Before Ichnos, Mr. Wilson served as General Counsel, Chief Compliance Officer, Corporate Secretary and Head of Human Resources at Teligent, Inc. Prior to Teligent, he was Vice President and Assistant General Counsel at Endo Pharmaceuticals following the acquisition of Par Pharmaceuticals. Mr. Wilson held multiple roles of increasing responsibility at Par over the course of 11 years, including Chief Compliance Officer.
“Rocket’s dynamic culture, long-term vision and unyielding devotion to patients drew me to this opportunity,” said Mr. Wilson. “I’m excited to work with the Rocket leadership team and contribute to the company’s success as it advances first-in-class gene therapies for rare, devastating diseases.”
Earlier in his career, Mr. Wilson held a role in the Licensing group at Schering-Plough. He earned his Juris Doctorate from Villanova University Charles Widger School of Law.
